Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28


The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2019 Feb 14:1-5. doi: 10.1080/21681805.2018.1551244. [Epub ahead of print]


Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.

Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB.

Cancer. 2018 Aug 1;124(15):3127-3135. doi: 10.1002/cncr.31404. Epub 2018 Apr 16.


Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urology. 2017 Dec;110:76-83. doi: 10.1016/j.urology.2017.08.024. Epub 2017 Aug 25.


Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.

Williams SB, Huo J, Dafashy TJ, Ghaffary CK, Baillargeon JG, Morales EE, Kim SP, Kuo YF, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urol Oncol. 2017 Oct;35(10):602.e1-602.e9. doi: 10.1016/j.urolonc.2017.05.022. Epub 2017 Jun 21.


Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.

McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):611-617. doi: 10.1111/iju.13387. Epub 2017 Jun 6.


Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.

Tosoian JJ, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE.

BJU Int. 2017 Dec;120(6):808-814. doi: 10.1111/bju.13911. Epub 2017 Jun 11.


Among Active Surveillance Candidates does Obesity Influence Tumor Aggressiveness and/or Location?

Freedland AR, Freedland SJ.

J Urol. 2017 Jul;198(1):4-5. doi: 10.1016/j.juro.2017.04.074. Epub 2017 Apr 22. No abstract available.


Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.

Vidal AC, Freedland SJ.

Eur Urol. 2017 Jul;72(1):78-83. doi: 10.1016/j.eururo.2016.10.011. Epub 2016 Oct 19. Review.


Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR.

J Urol. 2016 Nov;196(5):1408-1414. doi: 10.1016/j.juro.2016.06.086. Epub 2016 Jun 25.


Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.

Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE.

J Urol. 2017 Jan;197(1):122-128. doi: 10.1016/j.juro.2016.08.091. Epub 2016 Aug 26.


Treatment patterns for older veterans with localized prostate cancer.

Hoffman RM, Shi Y, Freedland SJ, Keating NL, Walter LC.

Cancer Epidemiol. 2015 Oct;39(5):769-77. doi: 10.1016/j.canep.2015.07.005. Epub 2015 Jul 27.


Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

Ross AE, D'Amico AV, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):1-6. doi: 10.1038/pcan.2015.31. Epub 2015 Jun 30. Review.


Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.

Moreira DM, Fleshner NE, Freedland SJ.

J Urol. 2015 Nov;194(5):1258-63. doi: 10.1016/j.juro.2015.04.113. Epub 2015 May 16.


A urine-based methylation signature for risk stratification within low-risk prostate cancer.

Jatkoe TA, Karnes RJ, Freedland SJ, Wang Y, Le A, Baden J.

Br J Cancer. 2015 Mar 3;112(5):802-8. doi: 10.1038/bjc.2015.7. Epub 2015 Feb 19.


Timing of curative treatment for prostate cancer: a systematic review.

van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG.

Eur Urol. 2013 Aug;64(2):204-15. doi: 10.1016/j.eururo.2013.02.024. Epub 2013 Feb 22. Review.


Obesity and prostate cancer: weighing the evidence.

Allott EH, Masko EM, Freedland SJ.

Eur Urol. 2013 May;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013. Epub 2012 Nov 15. Review.


Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.

Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. doi: 10.1038/pcan.2012.38. Epub 2012 Oct 16.


Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.

Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Prostate. 2013 Mar;73(4):409-17. doi: 10.1002/pros.22582. Epub 2012 Sep 19.


Active surveillance for prostate cancer: a systematic review of the literature.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS.

Eur Urol. 2012 Dec;62(6):976-83. doi: 10.1016/j.eururo.2012.05.072. Epub 2012 Jun 7. Review.


Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.

Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ, Keating NL.

Urology. 2012 Mar;79(3):537-45. doi: 10.1016/j.urology.2011.11.013. Epub 2012 Jan 13.


Supplemental Content

Loading ...
Support Center